Skip to Content

Ibandronate Pregnancy and Breastfeeding Warnings

Ibandronate is also known as: Boniva

Ibandronate Pregnancy Warnings

Bisphosphonates cause fetal harm in animals, and animal data suggest that uptake of bisphosphonates into fetal bone is greater than into maternal bone. Maternal deaths at the time of delivery were observed in female rats given this drug orally at doses greater than or equal to 3 times human exposure. Exposure of pregnant rats during the period of organogenesis resulted in visceral variations (renal pelvis ureter syndrome) and interference with natural delivery (dystocia). Dystocia could be partially reversed by calcium supplementation. In pregnant rats dosed orally maternal toxicity, including dystocia and mortality, fetal perinatal and postnatal mortality, were observed at doses equivalent to human exposure at the recommended daily and greater than or equal to 4 times the recommended once-monthly dose. There are no data on fetal risk and pregnancy in humans.

AU, UK: Use should be avoided. US: This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. AU TGA pregnancy category: B3 US FDA pregnancy category: C Comments: There is a theoretical risk of fetal harm (e.g., skeletal and other abnormalities) if pregnancy occurs after completing a course of bisphosphonate therapy.

See references

Ibandronate Breastfeeding Warnings

AU, UK: Use should be avoided. US: Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Boniva (ibandronate)." Roche Laboratories, Nutley, NJ.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. "Product Information. Boniva (ibandronate)." Roche Laboratories, Nutley, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.